Migraine is a common disorder affecting 12% of the U.S. population. Prophylaxis is recommended for patients who experience frequent migraines. Because current drugs used for prophylaxis are not 100% effective and cause adverse effects that affect compliance, new strategies have been studied to prevent headaches. One new pharmacologic strategy is to use an inhibitor of the calcitonin gene-related peptide (CGRP). As a class, the CGRP receptor inhibitors have reduced monthly migraine days and are well tolerated. This article will briefly review CGRP inhibitors in development.
LiptonRBBigalMEDiamondMFreitagFReedMLStewartWF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343-349.
2.
GoldbergLD. The cost of migraine and its treatment. Am J Manag Care. 2005;11(2suppl):S62-S67.
3.
GoadsbyPJLiptonRBFerrariMD. Migraine—current understanding and treatment. N Engl J Med. 2002;346:257-270.
4.
PuleddaFMessinaRGoadsbyPJ. An update on migraine: current understanding and future directions [published online ahead of print March 20, 2017]. J Neurol. doi:10.1007/s00415-017-8434-y.
